Literature DB >> 26474163

No scientific basis to restrict 8 weeks of treatment with ledipasvir/sofosbuvir to patients with hepatitis C virus RNA <6,000,000 IU/mL.

Thomas R O'Brien1, Jordan J Feld2, Shyam Kottilil3, Ruth M Pfeiffer4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26474163      PMCID： PMC4688210          DOI： 10.1002/hep.28292

Source DB:  PubMed          Journal:  Hepatology        ISSN： 0270-9139            Impact factor:   17.425


× No keyword cloud information.
  7 in total

1.  EASL Recommendations on Treatment of Hepatitis C 2015.

Authors: 
Journal:  J Hepatol       Date:  2015-04-21       Impact factor: 25.083

Review 2.  Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus.

Authors: 
Journal:  Hepatology       Date:  2015-08-04       Impact factor: 17.425

3.  Therapy for hepatitis C--the costs of success.

Authors:  Jay H Hoofnagle; Averell H Sherker
Journal:  N Engl J Med       Date:  2014-04-11       Impact factor: 91.245

4.  Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis.

Authors:  Kris V Kowdley; Stuart C Gordon; K Rajender Reddy; Lorenzo Rossaro; David E Bernstein; Eric Lawitz; Mitchell L Shiffman; Eugene Schiff; Reem Ghalib; Michael Ryan; Vinod Rustgi; Mario Chojkier; Robert Herring; Adrian M Di Bisceglie; Paul J Pockros; G Mani Subramanian; Di An; Evguenia Svarovskaia; Robert H Hyland; Phillip S Pang; William T Symonds; John G McHutchison; Andrew J Muir; David Pound; Michael W Fried
Journal:  N Engl J Med       Date:  2014-04-10       Impact factor: 91.245

5.  Successful Retreatment of Chronic HCV Genotype-1 Infection With Ledipasvir and Sofosbuvir After Initial Short Course Therapy With Direct-Acting Antiviral Regimens.

Authors:  Eleanor M Wilson; Sarah Kattakuzhy; Sreetha Sidharthan; Zayani Sims; Lydia Tang; Mary McLaughlin; Angie Price; Amy Nelson; Rachel Silk; Chloe Gross; Elizabeth Akoth; Hongmei Mo; G Mani Subramanian; Phillip S Pang; John G McHutchison; Anu Osinusi; Henry Masur; Anita Kohli; Shyam Kottilil
Journal:  Clin Infect Dis       Date:  2015-10-31       Impact factor: 9.079

6.  A SPECIAL MEETING REVIEW EDITION: Advances in the Treatment of Hepatitis C Virus Infection From EASL 2015: The 50th Annual Meeting of the European Association for the Study of the Liver • April 22-26, 2015 • Vienna, AustriaSpecial Reporting on:• Daclatasvir, Sofosbuvir, and Ribavirin Combination for HCV Patients With Advanced Cirrhosis or Posttransplant Recurrence: Phase 3 ALLY-1 Study• Efficacy and Safety of Grazoprevir and Elbasvir in Hepatitis C Genotype 1-Infected Patients With Child-Pugh Class B Cirrhosis (C-SALT Part A)• Ledipasvir/Sofosbuvir With Ribavirin Is Safe and Efficacious in Decompensated and Post Liver Transplantation Patients With HCV Infection: Preliminary Results of the Prospective SOLAR 2 Trial• Retreatment of Patients Who Failed 8 or 12 Weeks of Ledipasvir/Sofosbuvir-Based Regimens With Ledipasvir/Sofosbuvir for 24 Weeks• Sofosbuvir + Peginterferon/Ribavirin for 12 Weeks Vs Sofosbuvir + Ribavirin for 16 or 24 Weeks in Genotype 3 HCV Infected Patients and Treatment-Experienced Cirrhotic Patients With Genotype 2 HCV: The BOSON Study• Safety and Efficacy of the Combination Daclatasvir-Sofosbuvir in HCV Genotype 1-Mono-Infected Patients From the French Observational Cohort ANRS CO22 HEPATHER• C-SWIFT: Grazoprevir/Elbasvir + Sofosbuvir in Cirrhotic and Noncirrhotic, Treatment-Naive Patients With Hepatitis C Virus Genotype 1 Infection for Durations of 4, 6 or 8 Weeks and Genotype 3 Infection for Durations of 8 or 12 WeeksPLUS Meeting Abstract Summaries With Expert Commentary by: Steven L. Flamm, MD Chief, Liver Transplantation ProgramProfessor of Medicine and SurgeryNorthwestern University Feinberg School of MedicineChicago, Illinois.

Authors: 
Journal:  Gastroenterol Hepatol (N Y)       Date:  2015-06

7.  Subgroup differences in response to 8 weeks of ledipasvir/sofosbuvir for chronic hepatitis C.

Authors:  Thomas R O'Brien; Krystle A Lang Kuhs; Ruth M Pfeiffer
Journal:  Open Forum Infect Dis       Date:  2014-12-13       Impact factor: 3.835
  7 in total
  12 in total

Review 1.  Clinical Laboratory Testing in the Era of Directly Acting Antiviral Therapies for Hepatitis C.

Authors:  Eleanor M Wilson; Elana S Rosenthal; Sarah Kattakuzhy; Lydia Tang; Shyam Kottilil
Journal:  Clin Microbiol Rev       Date:  2016-10-19       Impact factor: 26.132

Review 2.  Shortening the duration of therapy for chronic hepatitis C infection.

Authors:  Benjamin Emmanuel; Eleanor M Wilson; Thomas R O'Brien; Shyam Kottilil; George Lau
Journal:  Lancet Gastroenterol Hepatol       Date:  2017-08-10

3.  Effectiveness of Ledipasvir-Sofosbuvir Combination in Patients With Hepatitis C Virus Infection and Factors Associated With Sustained Virologic Response.

Authors:  Norah A Terrault; Stefan Zeuzem; Adrian M Di Bisceglie; Joseph K Lim; Paul J Pockros; Lynn M Frazier; Alexander Kuo; Anna S Lok; Mitchell L Shiffman; Ziv Ben Ari; Lucy Akushevich; Monika Vainorius; Mark S Sulkowski; Michael W Fried; David R Nelson
Journal:  Gastroenterology       Date:  2016-08-24       Impact factor: 22.682

4.  Modeling HCV cure after an ultra-short duration of therapy with direct acting agents.

Authors:  Ashish Goyal; Yoav Lurie; Eric G Meissner; Marian Major; Natasha Sansone; Susan L Uprichard; Scott J Cotler; Harel Dahari
Journal:  Antiviral Res       Date:  2017-06-30       Impact factor: 5.970

Review 5.  Direct-acting antiviral agents for hepatitis C: structural and mechanistic insights.

Authors:  Matthias Götte; Jordan J Feld
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-05-05       Impact factor: 46.802

6.  Hepatitis C RNA assay differences in results: Potential implications for shortened therapy and determination of Sustained Virologic Response.

Authors:  Gavin Cloherty; Stephane Chevaliez; Christoph Sarrazin; Christine Herman; Vera Holzmayer; George Dawson; Benjamin Maasoumy; Johannes Vermehren; Heiner Wedemeyer; Jordan J Feld; Jean-Michel Pawlotsky
Journal:  Sci Rep       Date:  2016-10-20       Impact factor: 4.379

7.  Multicenter Comparison Study of both Analytical and Clinical Performance across Four Roche Hepatitis C Virus RNA Assays Utilizing Different Platforms.

Authors:  Johannes Vermehren; Evelyn Stelzl; Benjamin Maasoumy; Veronique Michel-Treil; Caterina Berkowski; Ed G Marins; Ellen E Paxinos; Enrique Marino; Heiner Wedemeyer; Christoph Sarrazin; Harald H Kessler
Journal:  J Clin Microbiol       Date:  2017-01-25       Impact factor: 5.948

8.  Analytical characteristics and comparative evaluation of Aptima HCV quant Dx assay with the Abbott RealTime HCV assay and Roche COBAS AmpliPrep/COBAS TaqMan HCV quantitative test v2.0.

Authors:  A Worlock; D Blair; M Hunsicker; T Le-Nguyen; C Motta; C Nguyen; E Papachristou; J Pham; A Williams; M Vi; B Vinluan; A Hatzakis
Journal:  Virol J       Date:  2017-04-04       Impact factor: 4.099

9.  Eight-Week Hepatitis C Treatment with New Direct Acting Antivirals Has a Better Safety Profile While Being Effective in the Treatment-Naïve Geriatric Population Without Liver Cirrhosis and Hepatitis C Virus-RNA < 6 Million IU/mL.

Authors:  Beshoy Yanny; Sammy Saab; Francisco Durazo; Nyan Latt; Amanda Mitry; Mira Moris Mikhail; Ramy M Hanna; Antony Aziz; Amandeep Sahota
Journal:  Dig Dis Sci       Date:  2018-09-27       Impact factor: 3.487

10.  Eight-week ledipasvir/sofosbuvir in non-cirrhotic, treatment-naïve hepatitis C genotype-1 patients with hepatitis C virus-RNA < 6 million: Single center, real world effectiveness and safety.

Authors:  Nyan L Latt; Beshoy T Yanny; Derenik Gharibian; Rita Gevorkyan; Amandeep K Sahota
Journal:  World J Gastroenterol       Date:  2017-07-14       Impact factor: 5.742
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.